Our Team

Experts in Radiation Sciences

The Akiram team has extensive experience in research within radiation sciences, cancer precision medicine, and drug discovery and development. The company has also recruited people with competence within production (CMC), as well as oncologists and hospital physicists who will be valuable in the clinical development.

The company’s CEO and founder Professor Marika Nestor, an award-winning cancer researcher, is the leader of a research group within cancer-targeted radiotherapy at Uppsala University, Department of Immunology, Genetics and Pathology, where she is also Chair of the research program Cancer Precision Medicine.

Chief advisor and co-founder Fredrik Frejd is Adjunct Professor in Molecular Radiotherapy with expertise in tumor-targeted substances. He is the Chief Scientific Officer at the biotech company Affibody AB, where he has led the development of drug candidates from pre-clinical to clinical phase II.

Co-founder and CTO Anja Mortensen is Assistant Professor in Molecular Medicine and Surgery at Karolinska Institutet, with extensive expertise in Experimental Oncology.

Project manager Tina Furebring has more than 25 years’ experience in developing of monospecific and bispecific antibodies for cancer treatment Extensive experiences in management of discovery, preclinical as well as early clinical projects.

CMC (Chemistry, Manufacturing and Control): Peter Frank has over 15 years´ experience developing biological drugs. He has previously worked at GE Healthcare and is currently Head of CMC at ITB Biopharmaceuticals.

Clinical advisor Jan Zedenius is Professor in surgery, specializing in Endocrine Surgery (e.g., the thyroid gland) at Karolinska Institutet and Chief Physician at Karolinska University Hospital. He is also president for the International Association of Endocrine Surgery, IAES.

Board of Directors

Board member Anna Törner, founder of SDS Life Science and SDS MedteQ, is an expert in drug development, with a special focus on regulatory affairs and statistics. She has a comprehensive background in developing regulatory strategies for clinical programs and study designs. Currently, Anna is active as a consultant, specializing in these areas. In addition, she serves on the boards of several companies, including Respiratorius AB (publ) and MedCap AB (publ).

Board member Peder Walberg, a licensed physician and economist, boasts an extensive career in the pharmaceutical industry, with experience in developing and commercializing drugs for rare diseases. His tenure includes key roles at Sobi, Wilson Therapeutics, Immedica, and Egetis Therapeutics. Additionally, Peder is actively engaged in his own consulting and investment ventures and holds board positions at Egetis Therapeutics AB (publ) and Immedica Pharma Holding AB.